Eli Lilly vs. Novo Nordisk: Better Obesity Drug Stock? These two healthcare leaders have a long history of competing against one another.
3 Under-the-Radar Stocks to Buy and Hold for a Decade All three could become highly prominent biotech companies within 10 years.
3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow Eli Lilly is winning the GLP-1 race right now, but it isn't resting on its laurels.
Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About The pharmaceutical company's flagship anti-obesity drug continues to bolster its efficacy and tolerability arguments.
Is Viking Therapeutics Stock Going to $100? Viking stock is known for soaring after positive news.
Why Pfizer Stock Popped Today Pfizer stock may not be cheap enough to buy yet, but it's certainly too cheap to sell.
CVS Health Just Announced Fantastic News to Eli Lilly Stock Investors It's another step in Eli Lilly's quest to cement its lead in the chronic weight management market.
Eli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success Eli Lilly knows that its GLP-1 windfall comes with an end date, so it is acting now to prepare.
Bull vs. Bear: The Quick Take on Viking Therapeutics Stock The pharmaceutical company's most promising drug candidate has some potential advantages over its rivals.
Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage Eli Lilly and Company just secured a big win as it looks to expand GLP-1 access, mending its partnership with top pharmacy benefit manager CVS Health.
5 Best Growth Stocks for the Next 10 Years These 5 long-term growth stocks could benefit from AI, cybersecurity, GLP-1 drugs, and fintech trends over the next decade
The Smartest Growth Stocks to Buy With $2,000 Right Now Most of the market's best-known growth names are overbought at this time. That's not the case for several off-the-radar alternatives.
Contrarian Opinion: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now Novo Nordisk lost its lead in the GLP-1 race, but Eli Lilly's valuation is a bit rich.
Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders? Hims & Hers is acquiring Australian telehealth platform Eucalyptus as part of its international expansion plan while using $350 million in convertible senior notes.
